DK2020444T3 - Defekte ikke-integrative lentivirale over-førselsvektorer til vacciner - Google Patents
Defekte ikke-integrative lentivirale over-førselsvektorer til vacciner Download PDFInfo
- Publication number
- DK2020444T3 DK2020444T3 DK07290980.7T DK07290980T DK2020444T3 DK 2020444 T3 DK2020444 T3 DK 2020444T3 DK 07290980 T DK07290980 T DK 07290980T DK 2020444 T3 DK2020444 T3 DK 2020444T3
- Authority
- DK
- Denmark
- Prior art keywords
- hiv
- lentiviral
- particle according
- vector particle
- immune response
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims description 188
- 230000002950 deficient Effects 0.000 title claims description 22
- 229960005486 vaccine Drugs 0.000 title description 10
- 230000005540 biological transmission Effects 0.000 title 1
- 239000002245 particle Substances 0.000 claims description 85
- 230000028993 immune response Effects 0.000 claims description 57
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 51
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 47
- 229920001184 polypeptide Polymers 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 108091033319 polynucleotide Proteins 0.000 claims description 30
- 102000040430 polynucleotide Human genes 0.000 claims description 30
- 239000002157 polynucleotide Substances 0.000 claims description 30
- 108020004414 DNA Proteins 0.000 claims description 28
- 108010061833 Integrases Proteins 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 28
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 27
- 241000700605 Viruses Species 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 230000000890 antigenic effect Effects 0.000 claims description 21
- 244000052769 pathogen Species 0.000 claims description 21
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 19
- 230000001717 pathogenic effect Effects 0.000 claims description 19
- 230000001681 protective effect Effects 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 230000035772 mutation Effects 0.000 claims description 14
- 241000713666 Lentivirus Species 0.000 claims description 12
- 101710205625 Capsid protein p24 Proteins 0.000 claims description 11
- 101710177166 Phosphoprotein Proteins 0.000 claims description 11
- 101710149279 Small delta antigen Proteins 0.000 claims description 11
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 claims description 11
- 108700004025 env Genes Proteins 0.000 claims description 11
- 241001430294 unidentified retrovirus Species 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 230000024932 T cell mediated immunity Effects 0.000 claims description 9
- 230000002163 immunogen Effects 0.000 claims description 9
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 230000035897 transcription Effects 0.000 claims description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- 208000031886 HIV Infections Diseases 0.000 claims description 6
- 108020005067 RNA Splice Sites Proteins 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 6
- 102220036548 rs140382474 Human genes 0.000 claims description 6
- 241000711573 Coronaviridae Species 0.000 claims description 5
- 230000028996 humoral immune response Effects 0.000 claims description 5
- 230000005923 long-lasting effect Effects 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 241000725619 Dengue virus Species 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 241000710772 Yellow fever virus Species 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000003362 replicative effect Effects 0.000 claims description 2
- 229940051021 yellow-fever virus Drugs 0.000 claims description 2
- 102100034343 Integrase Human genes 0.000 claims 4
- 229940033330 HIV vaccine Drugs 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 108020005091 Replication Origin Proteins 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 78
- 101000798079 Homo sapiens E3 ubiquitin-protein ligase TRAIP Proteins 0.000 description 75
- 101001017828 Homo sapiens Leucine-rich repeat flightless-interacting protein 1 Proteins 0.000 description 75
- 102100033303 Leucine-rich repeat flightless-interacting protein 1 Human genes 0.000 description 75
- 102100034349 Integrase Human genes 0.000 description 34
- 210000004443 dendritic cell Anatomy 0.000 description 34
- 230000014509 gene expression Effects 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 31
- 238000010361 transduction Methods 0.000 description 30
- 241000710886 West Nile virus Species 0.000 description 29
- 230000010354 integration Effects 0.000 description 26
- 230000026683 transduction Effects 0.000 description 26
- 230000003053 immunization Effects 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 238000002649 immunization Methods 0.000 description 15
- 108700019146 Transgenes Proteins 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 13
- 238000002255 vaccination Methods 0.000 description 12
- 230000010076 replication Effects 0.000 description 11
- 230000036039 immunity Effects 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 101710091045 Envelope protein Proteins 0.000 description 9
- 102100022297 Integrin alpha-X Human genes 0.000 description 9
- 101710188315 Protein X Proteins 0.000 description 9
- 241000711975 Vesicular stomatitis virus Species 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 108700004029 pol Genes Proteins 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000008348 humoral response Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 206010057293 West Nile viral infection Diseases 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000001173 tumoral effect Effects 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 108700004026 gag Genes Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 101150088264 pol gene Proteins 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 241000036569 Carp sprivivirus Species 0.000 description 4
- 108010022394 Threonine synthase Proteins 0.000 description 4
- 241000711970 Vesiculovirus Species 0.000 description 4
- NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 description 4
- SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000710831 Flavivirus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 102000004419 dihydrofolate reductase Human genes 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002743 insertional mutagenesis Methods 0.000 description 3
- 230000012223 nuclear import Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- YURDCJXYOLERLO-LCYFTJDESA-N (2E)-5-methyl-2-phenylhex-2-enal Chemical compound CC(C)C\C=C(\C=O)C1=CC=CC=C1 YURDCJXYOLERLO-LCYFTJDESA-N 0.000 description 2
- 241001302714 Aedes pseudoscutellaris Species 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 102220638993 Beta-enolase_H16C_mutation Human genes 0.000 description 2
- 241001674094 Boteke virus Species 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 241000219076 Calchaqui virus Species 0.000 description 2
- 241000702749 Carajas virus Species 0.000 description 2
- 241000711969 Chandipura virus Species 0.000 description 2
- 241000501789 Cocal virus Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001460770 Eel virus American Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 241000172083 Gray Lodge virus Species 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 241001109688 Isfahan virus Species 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 241001481498 Jurona vesiculovirus Species 0.000 description 2
- 241000897510 Klamath virus Species 0.000 description 2
- 241000172088 Kwatta virus Species 0.000 description 2
- 241000172089 La Joya virus Species 0.000 description 2
- 241001481497 Malpais Spring vesiculovirus Species 0.000 description 2
- 241001372913 Maraba virus Species 0.000 description 2
- 102220485636 Mitogen-activated protein kinase 15_K42A_mutation Human genes 0.000 description 2
- 241000479161 Mount Elgon bat virus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241001481499 Perinet vesiculovirus Species 0.000 description 2
- 241001641514 Pike fry sprivivirus Species 0.000 description 2
- 241000711965 Piry virus Species 0.000 description 2
- 241000172084 Porton virus Species 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 241001481504 Radi vesiculovirus Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 102220509593 Small integral membrane protein 10_H51A_mutation Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 2
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 241001329715 Tupaia virus Species 0.000 description 2
- 102220635504 Vacuolar protein sorting-associated protein 33A_D41A_mutation Human genes 0.000 description 2
- 241001517166 Vesicular stomatitis Alagoas virus Species 0.000 description 2
- 241000711973 Vesicular stomatitis Indiana virus Species 0.000 description 2
- 241000711959 Vesicular stomatitis New Jersey virus Species 0.000 description 2
- 241001481505 Yug Bogdanovac vesiculovirus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 101150030339 env gene Proteins 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 101150098622 gag gene Proteins 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000004726 long-term protective immunity Effects 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000009126 molecular therapy Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 108010089520 pol Gene Products Proteins 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 102200052245 rs199469625 Human genes 0.000 description 2
- 102220128858 rs200860772 Human genes 0.000 description 2
- 102220139188 rs35702995 Human genes 0.000 description 2
- 102220237139 rs376184349 Human genes 0.000 description 2
- 102220288357 rs572035776 Human genes 0.000 description 2
- 102220045124 rs587781846 Human genes 0.000 description 2
- 102200155054 rs80358230 Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000172078 BeAn 157575 virus Species 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 108010032795 CD8 receptor Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000252230 Ctenopharyngodon idella Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- -1 DNA or RNA Chemical class 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100025370 Keratin, type II cytoskeletal 71 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000711513 Mononegavirales Species 0.000 description 1
- 101000932479 Mus musculus Fms-related tyrosine kinase 3 ligand Proteins 0.000 description 1
- 102100021010 Nucleolin Human genes 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 102220497402 Oxysterol-binding protein-related protein 3_K71A_mutation Human genes 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000012827 T-B+ severe combined immunodeficiency due to gamma chain deficiency Diseases 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 201000007146 X-linked severe combined immunodeficiency Diseases 0.000 description 1
- UYRDHEJRPVSJFM-VSWVFQEASA-N [(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e,11z)-11-[4-[(e)-2-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C/1C=C(\C=C\[C@]23[C@@](O2)(C)C[C@@H](O)CC3(C)C)C(=O)O\1 UYRDHEJRPVSJFM-VSWVFQEASA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 108700010758 gag-pro Proteins 0.000 description 1
- 101150081889 gag-pro gene Proteins 0.000 description 1
- 108700010759 gag-pro-pol Proteins 0.000 description 1
- 101150061559 gag-pro-pol gene Proteins 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005960 long-lasting response Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108010044762 nucleolin Proteins 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- UTIQDNPUHSAVDN-UHFFFAOYSA-N peridinin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC=CC=C2/OC(=O)C(=C2)C=CC34OC3(C)CC(O)CC4(C)C)C)C(C)(O)C1 UTIQDNPUHSAVDN-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 102220146256 rs886059153 Human genes 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 108010038751 tax Gene Products Proteins 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (30)
- PATENTKRAY1. Anvendelse af en ikke-integratsv HIV-ientiviral vektorpartikel omfattende et defekt integraseprotein og yderligere omfattende et RNA-genom som er transkriptionsproduktet af et vektorgenom omfattende et polynukleotid kodende for mindst et antigent polypeptid, to LTR'er og en DNA-f!ap omfattende en cRPT og et GTS-domæner, ved fremstillingen af en immunogen sammensætning ti! fremkaldelse af et beskyttende immunrespons mod mindst en af nævnte antigene polypeptid for at forhindre infektion med et patogen eller maligne tilstande i et menneske der administreres med nævnte immunogene sammensætning omfattende doser af nævnte HIV ientiviral vektorpartikler i området fra 1 pg ti! 100 pg af p24-antigen, hvor nævnte defekte integraseprotein er en integrase som har en klasse i-mufation til specifikt at ændre sin integrase-aktivitet.
- 2. Anvendelse af en HIV-lentivirai vekforpartikel ifølge krav 1, hvor nævnte lentivirusvektor Ikke er repiikativ,
- 3. Anvendelse af en HIV-lentivirai vektorpartikel ifølge et hvilket som helst af kravene 1 til 2, hvor nævnte immunrespons er et beskyttende humoralt immunrespons.
- 4. Anvendelse af en HIV-lentivirai vektorpartikel ifølge et hvilket som helst af kravene 1 til 2, hvor nævnte immunrespons er et cellulært immunrespons.
- 5. Anvendelse af en HIV-ientivirai vektorpart!kel ifølge krav 4, hvor nævnte immunrespons er et GD8-medieref cellulært immunrespons.
- 6. Anvendelse af en HIV-ientiviral vektorpartikel ifølge krav 4, hvor nævnte immunrespons er et CD4-medieret cellulært immunrespons.
- 7. Anvendelse af en HIV-lentivirai vektorpartikel ifølge krav 1, hvor nævnte mutation er D64V.
- 8. Anvendelse af en HlV-lentiviral vektorpartikei ifølge et hvilket som helst af kravene 1 til 7, hvor det lentivirale genom er blottet for gag, pol og/eiler env lentiviral gener,
- 9. Anvendelse af en Hl V-lentiviral vektorpartikei ifølge et hvilket som helst af kravene 1 til 7, hvor det lentivirale genom er blottet for funktionelle gag, pol og/eiler env lentivirale gener.
- 10. Anvendelse af en HIV-ientivira! vektorpartikei ifølge et hvilket som helst af kravene 1 til 8, hvor det lentivirale genom er blottet for alle endogene kodende lentivirale sekvenser.
- 11. Anvendelse af en HIV-ientiviral vektorpartikei ifølge et hvilket som helst af kravene 1 til 10, hvor det lentivirale genom omfatter (a) en LTR5! og en LTR3!, (b) en psi-sekvens, (c) en DNA-flap omfattende en cRPT og et GTS-domæner og (d) en sekvens kodende for mindst en af nævnte polypeptid.
- 12. Anvendelse af en Η i V-lentivi ral vektorpartikei ifølge krav 11, hvor nævnte lentivirale genom yderligere omfatter et splejsningsdonorsted (SD), et spiejs-ningsacceptorsted (SA) og et Rev-responsivt element (RRE).
- 13. Anvendelse af en HiV-lentiviral vektorpartikei ifølge krav 11 til 12, hvor nævnte lentivirale genom yderligere omfatter et replikationorigin (ori).
- 14. Anvendelse af en HIV-ientiviral vektorpartikei ifølge et hvilket som helst af kravene 11 til 13, hvor nævnte lentivirale genom yderligere omfatter en ske-letbindingsregion (SAR) og / eller en matrixbindingsregion (MAR).
- 15. Anvendelse af en HIV-lentiviral vektorpartikei ifølge et hvilket som helst af kravene 1 til 14, hvor LTR’en er slettet fra promotoren og enhanceren af U3.
- 16. Anvendelse af en HIV-ientiviral vektorpartikei ifølge et hvilket som helst af U-raunnn 1 til 1 R hwnr ΠΜ Δ-fianot nmfattar alias' haetår af caia/aneama oam defineret i SEQ ID NO: 1 til 7, som afbildet i Figur 6.
- 17. Anvendelse af en HIV-lentiviral vektorpartikel ifølge et hvilket som helst af kravene 1 til 16, hvor mindst en af nævnte polypeptid er kodet af en sekvens der stammer fra genomet af et patogen.
- 18. Anvendelse af en HiV-lentiviral vektorparti kel ifølge krav 17, hvor nævnte patogen er en virus, især retrovirus, ientivirus, fiavivirus eller coronavirus, en bakterie eller en parasit.
- 19. Anvendelse af en HiV-lentiviral vektorpartikel ifølge krav 18, hvor mindst en af nævnte polypeptid er afledt fra kappen af AiDS-virus, herunder HIV-1 eller HIV-2, fra kapsidet af HIV eller fra kappen af gul feber-virussen, vestnilvi-russen, denguevirussen (DV), japanske hjernebetændelsevirussen (JEV) eller den SARS-associerede coronavirus.
- 20. Anvendelse af en HIV-lentiviral vektorpartikel ifølge et hvilket som helst af kravene 1 fil 16, hvor mindst en af nævnte polypeptid omfatter en tumorepitop eller antigen.
- 21. Anvendelse af en HIV-lentiviral vektorpartikel ifølge et hvilket som helst af kravene 1 til 20, hvor nævnte lentivirale vektor er pseudotype med et VSV-G-protein.
- 22. Anvendelse af en HiV-lentiviral vektorpartikel ifølge et hvilket som helst af kravene 1 til 21, hvor nævnte VSV-G-protein omfatter eller består af trans-membrane-domænet af Indiana VSV-G og ectodomainet af New Jersey-serotypen.
- 23. Anvendelse af en HiV-lentiviral vektorpartikel ifølge et hvilket som helst af kravene 1 til 22, hvor nævnte immunrespons er et tidligt immunrespons.
- 24. Anvendelse af en HiV-lentiviral vektorpartike! ifølge krav 23, hvor nævnte immimracnonc inHi iroroc cå tiHIInt cnm αη i ina aftesr aHmlnictrcstirincin af sammensætningen,
- 25. Anvendelse af en HIV-ientivirai vektorpartikel ifølge et hvilket som helst af kravene 1 til 24, hvor nævnte immunrespons er et langvarig immunrespons.
- 26. Anvendelse af en HiV-lentiviral vektorparti kel ifølge krav 25, hvor nævnte immunrespons stadig er beskyttende mindst to måneder efter administrationen af sammensætningen.
- 27. Anvendelse af en HIV-ientiviral vektorpartikel ifølge et hvilket som helst af kravene 1 til 26, hvor nævnte immunrespons i nævnte vært opnås ved en enkelt administration.
- 28. Anvendelse af en HIV-ientiviral vektorpartikel ifølge et hvilket som helst af kravene 1 til 27, som administreres i doser af nævnte HiV-lentiviral vektor i området fra 1 til 50 pg, mest foretrukket 1 til 10 pg.
- 29. Anvendelse af en HIV-ientiviral vektorpartikel ifølge et hvilket som helst af kravene 1 til 28, hvor nævnte sammensætning administreres ved en subkutan (s.c.) intradermal (i.d.), intramuskulær (l.m.) eller intravenøs (i.v.) injektion, en oral administration og en mucosal administration, især intranasal administration eller inhalation.
- 30. Anvendelse af en HIV-ientiviral vektorpartikel ifølge et hvilket som helst af kravene 1 til 29, for at forhindre infektion af værten med et patogen som en virus, en bakterie eller en parasit.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07290980.7A EP2020444B1 (en) | 2007-08-03 | 2007-08-03 | Defective non-integrative lentiviral transfer vectors for vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2020444T3 true DK2020444T3 (da) | 2017-09-11 |
Family
ID=38870600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07290980.7T DK2020444T3 (da) | 2007-08-03 | 2007-08-03 | Defekte ikke-integrative lentivirale over-førselsvektorer til vacciner |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2020444B1 (da) |
| DK (1) | DK2020444T3 (da) |
| ES (1) | ES2634144T3 (da) |
| HU (1) | HUE033517T2 (da) |
| PL (1) | PL2020444T3 (da) |
| PT (1) | PT2020444T (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0701253D0 (en) | 2007-01-23 | 2007-02-28 | Diagnostics For The Real World | Nucleic acid amplification and testing |
| EP2405945A4 (en) * | 2009-03-13 | 2012-09-12 | Lentigen Corp | NON-INTEGRAL RETROVIRAL VECTOR VACCINES |
| TR201819015T4 (tr) * | 2011-06-10 | 2019-01-21 | Bluebird Bio Inc | Adrenolökodi̇strofi̇ ve adrenomi̇yelonöropati̇ i̇çi̇n gen terapi̇ vektörleri̇ |
| EP2878674A1 (en) * | 2013-11-28 | 2015-06-03 | Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) | Stable episomes based on non-integrative lentiviral vectors |
| DK3684786T3 (da) * | 2017-09-22 | 2024-10-28 | Centre Nat Rech Scient | Muteret glycoprotein af vesikulær stomatitisvirus |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2872170B1 (fr) * | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| GB0526211D0 (en) * | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| WO2007091066A1 (en) * | 2006-02-07 | 2007-08-16 | Ucl Business Plc | Applications of non-integrating lentiviral vectors |
-
2007
- 2007-08-03 DK DK07290980.7T patent/DK2020444T3/da active
- 2007-08-03 PL PL07290980T patent/PL2020444T3/pl unknown
- 2007-08-03 PT PT72909807T patent/PT2020444T/pt unknown
- 2007-08-03 ES ES07290980.7T patent/ES2634144T3/es active Active
- 2007-08-03 HU HUE07290980A patent/HUE033517T2/en unknown
- 2007-08-03 EP EP07290980.7A patent/EP2020444B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2020444B1 (en) | 2017-05-31 |
| EP2020444A1 (en) | 2009-02-04 |
| ES2634144T3 (es) | 2017-09-26 |
| PL2020444T3 (pl) | 2017-10-31 |
| PT2020444T (pt) | 2017-08-29 |
| HUE033517T2 (en) | 2017-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6480028B2 (ja) | レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用 | |
| EP1667714B1 (en) | Consensus/ancestral immunogens | |
| KR20080066042A (ko) | 렌티바이러스 벡터 기반 백신 | |
| US8222029B2 (en) | Lentiviral vector-based vaccine | |
| DK2020444T3 (da) | Defekte ikke-integrative lentivirale over-førselsvektorer til vacciner | |
| EP2047861B1 (en) | Lentiviral gene transfer vectors suitable for iterative administration and their medicinal applications | |
| AU2013203404B2 (en) | Lentiviral gene transfer vectors and their medicinal applications | |
| Gallinaro | Integrase defective lentiviral vector as a vaccine platform for delivering HIV-1 antigens | |
| McKenna | Characterization and immunogenicity of recombinant rhabdoviral vaccine vectors expressing HIV-1 and SIV envelope proteins | |
| MXPA06003076A (en) | Consensus/ancestral immunogens |